Format

Send to

Choose Destination
Eur J Pharmacol. 2013 Feb 15;701(1-3):181-4. doi: 10.1016/j.ejphar.2013.01.009. Epub 2013 Jan 23.

Should antihistamines be re-considered as antiasthmatic drugs as adjuvants to anti-leukotrienes?

Author information

1
Department of Pharmacology and Pharmacotherapy, University Medical School of Pécs, Pécs, Hungary. Lorand.Bartho@aok.pte.hu

Abstract

In spite of histamine mimicking the symptoms of allergic bronchoconstriction and severe anaphylaxis, histamine antagonists most probably represent no effective treatment for these conditions. Anti-leukotrienes proved effective for preventing attacks of allergic asthma. In vitro evidence supports a supra-additive effect of histamine H1 receptor antagonists and anti-leukotrienes in vitro, in asthma models utilizing human bronchi. The same seems to hold true for human allergen provocation tests in vivo. We conclude that combinations of second-generation antihistamines and anti-leukotrienes deserve a large-scale clinical trial for preventing and/or treating attacks of allergic asthma. If useful, these drugs could provide a cost-effective alternative to some recent antiasthmatics. Given that redundant mechanisms may be included in asthma pathophysiology, other combinations (including thromboxane or platelet activating factor antagonists) could also be considered.

PMID:
23353593
DOI:
10.1016/j.ejphar.2013.01.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center